Genenta Science (GNTA) Competitors $3.18 +0.01 (+0.47%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. HRTX, AVIR, PRQR, SGMT, VTYX, TRDA, CRBU, BDTX, CABA, and TNXPShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), ProQR Therapeutics (PRQR), Sagimet Biosciences (SGMT), Ventyx Biosciences (VTYX), Entrada Therapeutics (TRDA), Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Heron Therapeutics Atea Pharmaceuticals ProQR Therapeutics Sagimet Biosciences Ventyx Biosciences Entrada Therapeutics Caribou Biosciences Black Diamond Therapeutics Cabaletta Bio Tonix Pharmaceuticals Genenta Science (NASDAQ:GNTA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Is GNTA or HRTX more profitable? Genenta Science has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Heron Therapeutics -0.62%N/A -0.40% Do analysts rate GNTA or HRTX? Heron Therapeutics has a consensus target price of $4.50, indicating a potential upside of 233.33%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Heron Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in GNTA or HRTX? 15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, GNTA or HRTX? Genenta Science has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Which has better earnings and valuation, GNTA or HRTX? Genenta Science has higher earnings, but lower revenue than Heron Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$9.64MN/AN/AHeron Therapeutics$144.29M1.72-$13.58M-$0.02-67.50 Does the media prefer GNTA or HRTX? In the previous week, Genenta Science's average media sentiment score of 1.46 beat Heron Therapeutics' score of 0.00 indicating that Genenta Science is being referred to more favorably in the media. Company Overall Sentiment Genenta Science Positive Heron Therapeutics Neutral SummaryHeron Therapeutics beats Genenta Science on 6 of the 11 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.80M$3.35B$6.11B$10.56BDividend YieldN/A2.29%5.69%4.75%P/E RatioN/A21.5785.4827.60Price / SalesN/A476.51624.19239.62Price / CashN/A47.1237.9261.55Price / Book4.2910.1413.136.76Net Income-$9.64M-$52.31M$3.30B$275.88M7 Day Performance-2.87%6.72%5.29%3.72%1 Month Performance-9.00%15.01%9.94%10.22%1 Year Performance-37.60%29.34%87.78%35.86% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science1.0849 of 5 stars$3.18+0.5%N/A-34.3%$57.80MN/A0.007Positive NewsAnalyst ForecastGap DownHRTXHeron Therapeutics3.5563 of 5 stars$1.27-0.4%$4.50+255.7%-32.7%$231.89M$149.69M-63.25300Positive NewsAnalyst ForecastAVIRAtea Pharmaceuticals1.9288 of 5 stars$2.87-1.6%$6.00+108.9%-12.9%$227.92MN/A-1.7870News CoverageAnalyst ForecastPRQRProQR Therapeutics2.2597 of 5 stars$2.14-2.5%$8.00+274.7%+16.4%$224.62M$20.46M-4.64180News CoveragePositive NewsAnalyst ForecastSGMTSagimet Biosciences2.8689 of 5 stars$6.84-1.2%$25.67+275.5%+76.4%$222.27M$2M-3.738News CoverageAnalyst ForecastVTYXVentyx Biosciences1.217 of 5 stars$3.11+2.5%$7.50+141.5%+87.7%$221.41MN/A-1.8530News CoverageAnalyst ForecastTRDAEntrada Therapeutics3.1239 of 5 stars$5.80-0.7%$25.67+342.6%-64.6%$220.58M$79.48M-3.26110Positive NewsAnalyst ForecastCRBUCaribou Biosciences1.8608 of 5 stars$2.34+1.5%$6.67+185.5%+33.5%$217.44M$9.99M-1.31100News CoverageAnalyst ForecastBDTXBlack Diamond Therapeutics3.4735 of 5 stars$3.79+1.5%$11.00+190.6%+6.8%$215.52MN/A16.4690News CoveragePositive NewsAnalyst ForecastCABACabaletta Bio2.7673 of 5 stars$2.34-1.9%$14.50+521.0%-42.1%$213.56MN/A-0.8650News CoveragePositive NewsAnalyst ForecastTNXPTonix Pharmaceuticals2.8127 of 5 stars$24.19-2.3%$70.00+189.4%+59.8%$212.04M$9.83M-0.6150Analyst Forecast Related Companies and Tools Related Companies Heron Therapeutics Competitors Atea Pharmaceuticals Competitors ProQR Therapeutics Competitors Sagimet Biosciences Competitors Ventyx Biosciences Competitors Entrada Therapeutics Competitors Caribou Biosciences Competitors Black Diamond Therapeutics Competitors Cabaletta Bio Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersMelt-up warning America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
